Terms ending in 2029
Every in-force patent on Mesoblast, Inc.'s record whose computed term ends in 2029, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,858,932 | Repair And/Or Reconstitution of Invertebral Discs In force · High confidence | Mesoblast, Inc. | In force | High confidence | |
| US 12,558,382 | Repair And/Or Reconstruction of Invertebral Discs In force · High confidence | Mesoblast, Inc. | In force | High confidence | |
| US 9,815,896 | Monoclonal Antibody STRO-4 In force · High confidence | Mesoblast, Inc. | In force | High confidence | |
| US 8,828,375 | Expansion of Haemopoietic Precursors In force · High confidence | Mesoblast, Inc. | In force | High confidence | |
| US 9,480,713 | Method for Treating Diabetic Renal Failure or Syndrome X In force · High confidence | Mesoblast, Inc. | In force | High confidence | |
| US 9,968,640 | Method for Treating or Preventing a Pancreatic Dysfunction In force · Medium confidence | Mesoblast, Inc. | In force | Medium confidence | |
| US 9,090,678 | Monoclonal Antibody STRO-4 In force · High confidence | Mesoblast, Inc. | In force | High confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.